Vyome Holdings (HIND) Asset Writedowns and Impairment (2020 - 2025)
Vyome Holdings (HIND) posted quarterly Asset Writedowns and Impairment of $197659.0 for Q3 2025, down 35.6% year-over-year from $306942.0 in Q3 2024, and up 267.59% quarter-over-quarter from -$117939.0 in Q2 2025.
Vyome Holdings (HIND) Asset Writedowns and Impairment (2020 - 2025) Analysis & Trends
Vyome Holdings' Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $197659.0 for Q3 2025.
- In Q3 2025, Asset Writedowns and Impairment fell 35.6% year-over-year to $197659.0; the TTM figure through Dec 2025 stood at $130659.0 (down 30.0% YoY), while the FY2025 annual figure was $130659.0, down 30.0% from the prior year.
- Asset Writedowns and Impairment for Q3 2025 stood at $197659.0, up from -$117939.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $11.3 million in Q4 2022, with the low at -$182000.0 in Q2 2022.
- The 5-year median for Asset Writedowns and Impairment is $48717.0 (2024), against an average of $1.0 million.
- The sharpest annual moves came in 2022 and 2024: Asset Writedowns and Impairment jumped 123716.67% in 2022, then slumped 600.0% in 2024.
- Vyome Holdings' Asset Writedowns and Impairment stood at $27000.0 in 2021, then soared by 41807.41% to $11.3 million in 2022, then tumbled by 101.28% to -$145000.0 in 2023, then jumped by 133.6% to $48717.0 in 2024, then jumped by 305.73% to $197659.0 in 2025.
- Business Quant data shows HIND's Asset Writedowns and Impairment at $197659.0 in Q3 2025, -$117939.0 in Q2 2025, and $50939.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 197,659.00 |
| Sep 30, 2025 | 197,659.00 |
| Jun 30, 2025 | -117,939.00 |
| Jun 30, 2025 | -117,939.00 |
| Mar 31, 2025 | 50,939.00 |
| Mar 31, 2025 | 50,939.00 |
| Dec 31, 2024 | 48,717.00 |
| Dec 31, 2024 | 48,717.00 |
| Sep 30, 2024 | 306,942.00 |
| Sep 30, 2024 | 306,942.00 |
| Jun 30, 2024 | -124,000.00 |
| Jun 30, 2024 | -124,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Dec 31, 2023 | -145,000.00 |
| Dec 31, 2023 | -145,000.00 |
| Sep 30, 2023 | 777,000.00 |
| Sep 30, 2023 | 777,000.00 |
| Jun 30, 2023 | 136,000.00 |
| Jun 30, 2023 | 136,000.00 |